Hodgkin Lymphoma New Combo-Steps
|
|
- Elvin Claud Nicholson
- 5 years ago
- Views:
Transcription
1 New Drugs In Hematology Hodgkin Lymphoma New Combo-Steps Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center Monday, May 9, :55-3:10 p.m
2 Combinations with Immune Checkpoint Inhibitors Ledford, H: Nature, April 2016
3 Development of Anti-PD1/PDL1-Based Therapy Ibrutinib Revlimid Brentuximab Vedoton a-cd20 PD1/PDL1 mab HDACi Chemo therapy Urelumab (4-1BB) Ipililumab (CTAL4)
4 % Response rate Updated from Betlevi and Younes, Hematology Am Soc Hematol Educ Program Smith, K et al : Hodgkin Lymphoma, Hoffan Textbook of Hematology 2015 (In Press) Single agent activity of novel agents in relapsed chl High response rates - Potentially combinable at full doses 75 CR PR
5 Hodgkin Lymphoma : Future Directions Strategy A Strategy B PD1/PDL1 antibodies Chemo therapy PI3Ki mtori Chemo therapy Brentuximab vedotin PI3Ki mtori Brentuximab Vedotin + PD1/PDL1 antibody HDACi HDACi
6 Response adapted salvage therapy for transplant eligible HL 27% 45 patients Brentuximab Vedotin 1.2mg/kg Qwk x 3 followed by 1 wk rest Qwk x 3 followed by 1 wk rest R e s t a g e PET- 73% PET+ Stem cell collection => BEAM ASCT Augmented ICE Overall 76% achieved PET-/CR and proceeded to ASCT 69% PET- Stem cell collection => BEAM ASCT Alison Moskowitz et al, Lancet Oncology 2015
7 Tumour reduction after brentuximab vedotin Data shows PET status according to the Deauville scores of 1 5 Alison J Moskowitz, et al The Lancet Oncology,, 2015,
8 Nivolumab + Brentuximab Salavage Therapy for HL Brentuximab Vedotin 1.8mg/kg Nivolumab 240 mg Q 3wks x 4 R e s t a g e PR/CR < PR Stem cell collection => BEAM ASCT Chemo salvage Stem cell collection => BEAM ASCT
9 Development of Anti-PD1/PDL1-Based Therapy Ibrutinib Revlimid Brentuximab Vedoton a-cd20 PD1/PDL1 mab HDACi Chemo therapy Urelumab (4-1BB) Ipililumab (CTAL4)
10 Hodgkin and Reed Sternberg (HRS) Cells EBV Infection 9p24.1 Gene amplification CIITA-BX Gene fusion B2MG mutations JAK2 PDL1 MHC-II MHC-I PD1/PDL1 Antibodies JAK2i CD30 PD1 T cells HDACi Brentuximab Vedotin Chemotherapy
11 DAC Inhibitors: Regulation of Cell Survival and Immunity DACs Epigenetic effects on gene expression Increased p21 Decreased STAT6 Decreased Bcl-xL Caspase activation DAC inhibitor Inhibition of STAT6-mediated T H 2 cytokine/chemokine secretion/tarc Angiogenesis Cell-cycle arrest and apoptosis Favorable anti-tumor immune response Tumor response
12 DAC Inhibitors in HL: Regulation of Cell Survival and Immunity Before therapy After Aza After MGCD0103 CD8+ CD4+ PD-1
13 Panobinostat in Patients with Relapsed/Refractory HL 40 mg (fixed dose) orally, 3 times/week Younes A, et al. Blood. 2009;114: Abstract 923. Week Restage: If no PD Give Panobinostat until PD or tox
14 Best % Change in SPD From Baseline (index lesions only) Panobinostat Phase II Study in Relapsed HL % of patients with tumor reduction Active 75 Discontinued PD patients - SD (0%) PR 6 patients - off AE prior to Eval 1 1 patient - withdrew consent prior to Eval 1 1 patient - pending Eval 1 measurements patients with SPD < 50% had new lesions at Eval 1 Younes A,,Soreda A,, et al. JCO 2012
15 Panobinostat Downregulates PD-1 on T cells of Patients with Relapsed HL in Vivo Patient 1 Patient 2 CD8+ CD4+ CD8+ CD4+ Pretreatment Day 8 Day 15 PD1 Oki Y and Younes A - Blood Cancer J Aug; 4(8): e236.
16 HDACi Upregulate OX40L on HRS Cells Inhibition of T-reg function Buglio D, et al BLOOD 2011
17 Phase I/II Study of Entinostat (HDACi) + Pembrolizumab (anti-pd1) Entinostat Pembro Week
18 Development of Anti-PD1/PDL1-Based Therapy Ibrutinib Revlimid Brentuximab Vedoton a-cd20 PD1/PDL1 mab HDACi Chemo therapy Urelumab (4-1BB) Ipililumab (CTAL4)
19 Emerging Role for Chemo-FreeTherapy Newly diagnosed follicular lymphoma* 100% 75% 50% CR PR 25% 0% R + Lenalidomide R + Bendamustine R + CHOP R+ Ibrutinib R+ Len + Ibrutinib
20 Development of Anti-PD1/PDL1-Based Therapy Ibrutinib Revlimid Brentuximab Vedoton a-cd20 PD1/PDL1 mab PI3Ki/ mtori Chemo therapy Urelumab (4-1BB) Ipililumab (CTAL4)
21 Rationale for combining Ibrutinib with PD1/PDL1 antibodies T cell PD1 ITK IBRUTINIB TCR MHC I/II PD1 PD-L1 PD-L2 BTK BCR Malignant B Cell
22 Ibrutinib in combination with anti PD-L1 induces an antitumor immune response A20 mouse B cell lymphoma model 2015 by National Academy of Sciences Idit Sagiv-Barfi et al. PNAS 2015;112:E966-E972
23 The combination of ibrutinib with anti PD-L1 reduces tumor burden in 4T1 (Mouse Tripple Negative Breast Carcinoma) tumor-bearing mice by National Academy of Sciences Idit Sagiv-Barfi et al. PNAS 2015;112:E966-E972
24 PCI32765-LYM-1002: Study Design Nivolumab + Ibrutinib in relapsed B-cell malignancies Part A n=18 (Dose Optimization) Part B (n=30 in each cohort) (Expansion Cohort: Two-stage design) B 1: I: 420 mg/qd PO + N: 3 mg/kg/q14d A-1 I: 420 mg, po, qd N: 3mg/kg, i.v., q14d A-2 I: 560 mg, p.o., qd N: 3 mg/kg, i.v., q14d B1: CLL (del 17p or del 11q) B 2 and B 3: I: 560 mg/qd PO + N: 3 mg/kg/q14d B2: Follicular Lymphoma B3: DLBCL
25 Development of Anti-PD1/PDL1-Based Therapy Ibrutinib Revlimid Brentuximab Vedoton a-cd20 PD1/PDL1 mab HDACi Chemo therapy Urelumab (4-1BB) Ipililumab (CTAL4)
26 Development of Anti-PD1/PDL1-Based Therapy Frontline Regimens PD1/PDL1 antibody + DLBCL FL HL G-CHOP G-Benda G-CHOP ABVD
27 Phase I/II ABVD + Nivolumab in Advances Stage HL PET2 ABVD ABVD ABVD ABVD ABVD ABVD Nivo Nivo Nivo Nivo Nivo Nivo Nivo Nivo Nivo Nivo Nivo Nivo Nivo Nivo Nivo Nivo Nivo Nivo Nivo Nivo Nivo Nivo Nivo Nivo - ABVD ABVD ABVD ABVD ABVD ABVD PET2 + ABVD ABVD ABVD ABVD Nivo Nivo Nivo Nivo Nivo Nivo
28 Evaluating ctdna in Curable Lymphomas (HL and DLBCL) ctdna DLBCL RCHOP + Nivo HL ABVD + Nivo Months
Treatment Approaches in Relapsed/Refractory HL. Brentuximab Vedo=n. Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Ke=ering Cancer Center
Treatment Approaches in Relapsed/Refractory HL Brentuximab Vedo=n Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Ke=ering Cancer Center Thursday March 15, 2018: 10:15-10:30 am 1992 (Cell): Durkop
More informationBrentuximab Vedotin. Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center
Brentuximab Vedotin Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center U.S. Cancer Statistics 2016 300.000 249.260 224.390 200.000 180.890 Incidence 100.000 95.270 76.960
More informationLinfoma de Hodgkin. Novos medicamentos. Otavio Baiocchi CRM-SP
Linfoma de Hodgkin Novos medicamentos Otavio Baiocchi CRM-SP 96.074 Hodgkin Lymphoma Unique B-cell lymphoma HRS malignant cells Scattered malignant Hodgkin-Reed-Sternberg (RS) cells in a background of
More informationRelapsed/Refractory Hodgkin Lymphoma
Relapsed/Refractory Hodgkin Lymphoma Anas Younes, MD Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center New York, New York, United States Case Study 32-year-old woman was diagnosed with stage
More informationChemotherapy-based approaches are the optimal second-line therapy prior to stem cell transplant in relapsed HL
Lymphoma & Myeloma 2015 Chemotherapy-based approaches are the optimal second-line therapy prior to stem cell transplant in relapsed HL Jeremy S. Abramson, MD Relevant Disclosure Consulting for Seattle
More informationHodgkin Lymphoma Nivolumab
New Drugs In Hematology Hodgkin Lymphoma Nivolumab Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center Monday, May 9, 2016 2:10-2:25 p.m immunotherapy modalities CAR T Cells
More informationA CME-certified Oncology Exchange Program
A CME-certified Oncology Exchange Program Jointly provided by Potomac Center for Medical Education and Rockpointe Supported by an educational grant from Seattle Genetics, Inc. Re-treatment with BV Bartlett
More information2018 KSMO Immune Oncology Forum. Immune checkpoint inhibitors in hematologic. malignancies: evidences and perspectives 서울아산병원종양내과 홍정용
2018 KSMO Immune Oncology Forum Immune checkpoint inhibitors in hematologic malignancies: evidences and perspectives 서울아산병원종양내과 홍정용 2018-07-18 Contents Introduction Immune checkpoint inhibtors in lymphomas
More informationCheckpoint Blockade in Hematology and Stem Cell Transplantation
Checkpoint Blockade in Hematology and Stem Cell Transplantation Saad S. Kenderian, MD Assistant Professor of Medicine and Oncology Mayo Clinic College of Medicine October 14, 2016 2015 MFMER slide-1 Disclosures
More informationWhat is the best second-line approach to induce remission prior to stem cell transplant? Single agent brentuximab vedotin
What is the best second-line approach to induce remission prior to stem cell transplant? Single agent brentuximab vedotin Alison Moskowitz, MD Assistant Attending, Lymphoma Service Memorial Sloan Kettering
More informationBrentuximab Vedotin in Lymphomas
New Drugs In Hematology Brentuximab Vedotin in Lymphomas Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center Monday, May 9, 2016 9:15-9:45 a.m U.S. Cancer Statistics 2016 300.000
More informationWelcome and Introductions
Update on Hodgkin Lymphoma Matthew J Matasar, MD, MS Physician, Lymphoma and Adult BMT Services Director, Lymphoma Survivorship Clinic Memorial Sloan Kettering Cancer Center New York, NY April 1, 2016
More informationNovel approaches of ac.ve immune therapy in lymphoma. Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan- Ke=ering Cancer Center
Novel approaches of ac.ve immune therapy in lymphoma Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan- Ke=ering Cancer Center Therapeutic strategies to overcome immune tolerance to cancer Native
More informationNew Agents Beyond Brentuximab vedotin for Hodgkin Lymphoma. Stephen M. Ansell, MD, PhD Professor of Medicine Mayo Clinic
New Agents Beyond Brentuximab vedotin for Hodgkin Lymphoma Stephen M. Ansell, MD, PhD Professor of Medicine Mayo Clinic Disclosures for Stephen Ansell, MD, PhD In compliance with ACCME policy, Mayo Clinic
More informationNavigating Treatment Pathways in Relapsed/Refractory Hodgkin Lymphoma
Welcome to Managing Hodgkin Lymphoma. I am Dr. John Sweetenham from Huntsman Cancer Institute at the University of Utah. In today s presentation, I will be discussing navigating treatment pathways in relapsed
More informationKamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA
Kamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA Objectives Describe the current standard approach for patients with relapsed/refractory
More informationImmune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic
Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Assess the efficacy and safety of brentuximab vedotin in investigational settings, such as in combination with AVD for patients with newly diagnosed HL, as consolidation
More informationMariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro. Immune checkpoint inhibition in DLBCL
Mariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro Immune checkpoint inhibition in DLBCL Immunotherapy: The Cure is Inside Us Our immune system prevents or limit infections
More informationRelapse After Transplant: Next Steps for Patients with Hodgkin Lymphoma
Hi! My name is Alison Moskowitz. I am an attending at Memorial Sloan Kettering Cancer Center within the Lymphoma Department. I am speaking on behalf of ManagingHodgkinLymphoma.com. I will be discussing
More informationCheckpoint Inhibition in Hodgkin s Lymphoma John Kuruvilla, MD & Rob Laister, PhD
Checkpoint Inhibition in Hodgkin s Lymphoma John Kuruvilla, MD & Rob Laister, PhD Disclosures for Rob Laister Research Support Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific
More informationTreating for Cure or Palliation: Difficult Decisions for Older Adults with Lymphoma
Treating Frail Adults With Common Malignancies: Best Evidence to Personalize Therapy Treating for Cure or Palliation: Difficult Decisions for Older Adults with Lymphoma Raul Cordoba, MD, PhD Lymphoma Unit
More informationHodgkin Lymphoma. Barbara Pro, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Chicago, Illinois
Hodgkin Lymphoma Barbara Pro, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Chicago, Illinois Hodgkin Lymphoma Successes and Challenges The success 80 % of patients achieve
More informationCARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre
CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS
More informationAggressive lymphomas ASH Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV
Aggressive lymphomas ASH 2015 Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV CHOP 1992 2002 R-CHOP For DLBCL High dose chemo With PBSCT Aggressive lymphomas 1.DLBCL 2.Primary Mediastinal Lymphoma 3.CNS
More informationImmune checkpoint inhibitors in lymphoma. Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust
Immune checkpoint inhibitors in lymphoma Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust Aims How immune checkpoint inhibitors work Success of immune checkpoint
More informationMantle Cell Lymphoma New scenario and concepts in front-line treatment for young pa:ents
Mantle Cell Lymphoma New scenario and concepts in front-line treatment for young pa:ents Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Ke=ering Cancer Center Friday March 16, 2018: 11:15-11:30
More informationThe Immunotherapy of Oncology
The Immunotherapy of Oncology The 30-year Overnight Success Story M Avery, BIOtech Now 2014 Disclosures: Geoffrey R. Weiss, M.D. None The History A. Chekov: It has long been noted that the growth of malignant
More informationBendamustine for Hodgkin lymphoma. Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service
Bendamustine for Hodgkin lymphoma Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service Bendamustine in Hodgkin lymphoma Bifunctional molecule Nitrogen mustard component (meclorethamine)
More informationConfronto Real world e studi registrativi
Confronto Real world e studi registrativi V. Pavone San Giovanni Rotondo 8 Novembre 2018 U.O Ematologia Az.Osp.Card.G.Panico MEDICAL NEED IN HL OUTCOME REDUCE TOXICITY IMPROVE FIRST LINE RISK-ADAPTED STRATEGY
More informationWhat are the hurdles to using cell of origin in classification to treat DLBCL?
What are the hurdles to using cell of origin in classification to treat DLBCL? John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical
More informationNovel Therapeutic Targets for Hodgkin Lymphoma
Hodgkin Lymphoma:...Therapeutic Biology Novel Therapeutic Targets for Hodgkin Lymphoma Antonello Pinto Hematology-Oncology and Stem Cell Transplantation Unit Department of Hematology National Cancer Institute,
More informationPD-1/PD-L1 inhibitors in hematological malignancies, with focus on Lymphoid Malignancies
PD-1/PD-L1 inhibitors in hematological malignancies, with focus on Lymphoid Malignancies Professor Lim Soon Thye Head, Division of Medical Oncology National Cancer Centre Singapore Head, Singhealth Duke-NUS
More informationAdvances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma
Wang et al. Journal of Hematology & Oncology (2018) 11:57 https://doi.org/10.1186/s13045-018-0601-9 REVIEW Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma Yucai Wang 1, Grzegorz
More informationGerman Hodgkin Study Group
German Hodgkin Study Group Deutsche Hodgkin Studiengruppe Avoiding Relapse of Hodgkin Lymphoma: Have We Moved The Needle? Andreas Engert, MD Chairman, German Hodgkin Study Group University Hospital of
More informationNivolumab in Hodgkin Lymphoma
Nivolumab in Hodgkin Lymphoma Stephen M. Ansell, MD, PhD Professor of Medicine Chair, Lymphoma Group Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers Squibb Celldex Therapeutics Seattle
More informationRelapsed/Refractory Hodgkin Lymphoma
Relapsed/Refractory Hodgkin Lymphoma Robert Chen, MD Associate Professor of Medicine Co-Leader of Lymphoma Disease Team Associate Director of Toni Stephenson Lymphoma Center City of Hope National Medical
More informationAGRESSIVE LYMPHOMAS - FUTURE. Dr Stéphane Doucet CHUM
AGRESSIVE LYMPHOMAS - FUTURE Dr Stéphane Doucet CHUM What are clinical trials? Clinical trials are carefully planned research studies where the most-promising discoveries and results from laboratory studies
More informationPembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study
Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study Craig H. Moskowitz, 1 Pier Luigi Zinzani, 2 Michelle A. Fanale, 3 Philippe Armand, 4 Nathalie Johnson, 5 John
More informationHaemato-Oncology ESMO PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY. Development and clinical experience Monique Minnema, hematologist
Haemato-Oncology ESMO PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Development and clinical experience Monique Minnema, hematologist Consultancy for disclosures Amgen, Celgene, Jansen Cilag, BMS, Takeda Immune
More informationDoes BV as part of salvage impact outcome?
Does BV as part of salvage impact outcome? Craig Moskowitz, MD Steven A. Greenberg Chair in Lymphoma Research Member, Memorial Sloan Kettering Cancer Center Professor of Medicine, Weill Medical College
More informationImmunotherapy on the Horizon
Immunotherapy on the Horizon Andrew L. Coveler Assistant Professor of Medicine, Division of Oncology University of Washington Assistant Member Fred Hutchinson Cancer Research Center Image: NASA.gov 1 2
More informationThe case against maintenance rituximab in Follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc.
The case against maintenance rituximab in Follicular lymphoma Jonathan W. Friedberg M.D., M.M.Sc. Follicular lymphoma: What are goals of treatment? Change natural history of disease: Decrease transformation
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationHistology independent indications in Oncology
CHMP Oncology Working Party Workshop Histology independent indications in Oncology What have we learnt from the anti PD1- PDL1 story? J Camarero (CHMP alternate ES, OncWP) Disclaimers the views presented
More informationImmunotherapy in haematological malignancies. Michele Ghielmini Oncology Institute of Southern Switzerland Bellinzona
Immunotherapy in haematological malignancies Michele Ghielmini Oncology Institute of Southern Switzerland Bellinzona Conflicts of interest Roche Celgene Mundipharma Janssen Gilead Bayer Millenium What
More informationAssessing the Emerging Role of Checkpoint Inhibition and Other Immune Therapies in Lymphoma
CME Assessing the Emerging Role of Checkpoint Inhibition and Other Immune Therapies in Lymphoma Dates of certification: July 31, 2016, to July 31, 2017 Medium: Print with online posttest, evaluation, and
More informationBabis Andreadis, MD, MSCE Associate Professor of Medicine UCSF. Outline
ANCO Update in Lymphomas 2017 Babis Andreadis, MD, MSCE Associate Professor of Medicine UCSF Outline DLBCL Incorporating biomarkers in treatment choice CART19 therapy is here Mantle Cell Lymphoma: Induction
More informationPractical Application of PET adapted Therapy in Hodgkin Lymphoma
Practical Application of PET adapted Therapy in Hodgkin Lymphoma Matthew Matasar, MD Lymphoma and Adult BMT Services Director, Lymphoma Survivorship Clinic Memorial Sloan Kettering Cancer Center New York,
More informationUse of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories
Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion
More informationAlexander Fosså, M.D. PhD.
Alexander Fosså, M.D. PhD. Current position: Senior Consultant, Department of Medical Oncology Oslo University Hospital Focus of work: - Malignant lymphoma - Chemotherapy, immunotherapy, radiotherapy -
More informationImmunotherapy Approaches in Lymphoma
Immunotherapy Approaches in Lymphoma John Kuruvilla MD FRCPC 1 Disclosures for John Kuruvilla MD Research Support Employee Leukemia and Lymphoma Society US, Rasch Foundation Roche, N/A Consultant Abbvie,
More informationLymphoma 101. Nathalie Johnson, MDPhD. Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University
Lymphoma 101 Nathalie Johnson, MDPhD Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University Disclosures Consultant and Advisory boards for multiple companies
More informationDr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta
Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge ASH 2012 Atlanta DLBCL How to improve on R-CHOP What at relapse Mantle cell lymphoma Do we cure patients Treatment at relapse Follicular lymphoma Watch and
More informationRichter s Syndrome: Risk, Predictors and Treatment
Richter s Syndrome: Risk, Predictors and Treatment 10/23/2015 John N. Allan MD Assistant Professor of Medicine Division of Hematology and Medical Oncology CLL Research Center Weill Cornell Medicine Agenda
More informationIndolent Lymphomas and Hodgkin Lymphoma: Achieving Curability
Indolent Lymphomas and Hodgkin Lymphoma: Achieving Curability Bruce D. Cheson, M.D. Georgetown University Hospital Lombardi Comprehensive Cancer Center Washington, D.C. Di$clo$ure$ Consulting & advisory
More informationClinical Advances in Lymphoma
Conflicts of Interest Clinical Advances in Lymphoma Alex F. Herrera, MD Assistant t Professor Department of Hematology and HCT City of Hope BMS research funding (institutional), consultancy Genentech research
More informationPET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma. Ranjana H. Advani, MD
PET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma Ranjana H. Advani, MD Stanford Cancer Institute Management of Hodgkin Lymphoma Learning Objectives Review risk adapted strategies
More informationBTK Inhibitors and BCL2 Antagonists
BTK Inhibitors and BCL2 Antagonists Constantine (Con) S. Tam Director of Haematology, St Vincent s Hospital Melbourne; Lead for Chronic Lymphocytic Leukemia and Indolent Lymphoma, Peter MacCallum Cancer
More informationPost-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy
Post-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy Lee S. Schwartzberg, MD, FACP Chief, Division of Hematology Oncology; Professor of Medicine, The University of Tennessee; The West
More informationManagement of high-risk diffuse large B cell lymphoma: case presentation
Management of high-risk diffuse large B cell lymphoma: case presentation Daniel J. Landsburg, MD Assistant Professor of Clinical Medicine Perelman School of Medicine University of Pennsylvania January
More informationROB LOWN SOUTHAMPTON HODGKIN LYMPHOMA IN THE ELDERLY
ROB LOWN SOUTHAMPTON HODGKIN LYMPHOMA IN THE ELDERLY EPIDEMIOLOGY HODGKIN LYMPHOMA - INCIDENCE EPIDEMIOLOGY HODGKIN LYMPHOMA - MORTALITY EPIDEMIOLOGY HODGKIN LYMPHOMA - MORTALITY BY AGE NUMBER OF PEOPLE
More informationConstan'ne S Tam Victorian Comprehensive Cancer Center Melbourne, Australia
Constan'ne S Tam Victorian Comprehensive Cancer Center Melbourne, Australia BGB-3111: Kinase Selec.vity Rela.ve to Ibru.nib Equipotent against BTK compared to ibru.nib Higher selec.vity vs EGFR, ITK, JAK3,
More informationNew agents for recurrent FL
Lymphoma and Myeloma 2015 Meeting New agents for recurrent FL Sven de Vos, MD, PhD Director, UCLA Lymphoma Program Los Angeles, CA Indolent Lymphoma Percent Survival Year 60 mos 120 mos 1944-54 29.3 17.2
More informationLymphoma John P. Leonard, M.D.
Lymphoma 2017 John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Vice Chairman, Department of Medicine Disclosures Consulting
More informationMMAE disrupts cell division and triggers apoptosis. Pola binds to cell surface antigen CD79b. Pola is internalized; linker cleaves, releasing MMAE
Adding Polatuzumab Vedotin (Pola) to Bendamustine and Rituximab () Treatment Improves Survival in Patients With Relapsed/Refractory DLBCL: Results of a Phase II Clinical Trial Abstract S802 Sehn LH, Kamdar
More informationChanging the landscape of treatment in Peripheral T-cell Lymphoma
Changing the landscape of treatment in Peripheral T-cell Lymphoma Luis Fayad Associate Professor MD Anderson Cancer Center Department of Lymphoma and Myeloma 1 6 What is peripheral 2008 WHO CLASSIFICATION
More informationTreatment Landscape in R/R DLBCL Novel Targets and Strategies. Wyndham H. Wilson, M.D., Ph.D. Senior Investigator
Treatment Landscape in R/R DLBCL Novel Targets and Strategies Wyndham H. Wilson, M.D., Ph.D. Senior Investigator Gene-expression profiling of DLBCL subtypes Roschewski, M. et al. (2013) Nat. Rev. Clin.
More informationPET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma
PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationGLSG/OSHO Study Group. Supported by Deutsche Krebshilfe
GLSG/OSHO Study Group Supported by Deutsche Krebshilfe founded in 1985 Comparison of Two Consecutive Study Generations of the GLSG Overall Survival Follicular Lymphomas Questions for the Next Steps of
More informationAggressive NHL and Hodgkin Lymphoma. Dr. Carolyn Faught November 10, 2017
Aggressive NHL and Hodgkin Lymphoma Dr. Carolyn Faught November 10, 2017 What does aggressive mean? Shorter duration of symptoms Generally need treatment at time of diagnosis Immediate, few days, few weeks
More informationLymphoma- Med A-new drugs and treatments
Lymphoma- Med A-new drugs and treatments Silvia Montoto Lisbon, 19/03/2018 #EBMT18 www.ebmt.or Disclosures: Roche, Gilead Silvia Montoto Lisbon, 19/03/2018 #EBMT18 www.ebmt.or Outline Lymphoma- what is
More informationNovita da EHA 2016 Copenhagen Linfomi
Firenze, 16th September 2016 Marco Ladetto MD, Az Osp Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy EU Novita da EHA 2016 Copenhagen Linfomi THREE QUESTIONS TO ADDRESS: 1. Is ASCT still the
More informationPI3K Inhibitors. Anas Younes, M.D. chief, Lymphoma Service Memorial Sloan Kettering Cancer Center
PI3K Inhibitors Anas Younes, M.D. chief, Lymphoma Service Memorial Sloan Kettering Cancer Center Targeting PI3K/AKT/mTOR Pathway PI 3-kinase Α, β, γ, δ Idelalisib Duvelisib Copanlisib TGR-122 Buparlisib
More informationResponse Adapted treatment of chl using BV in first line. Massimo Federico University of Modena and Reggio Emilia Italy
Response Adapted treatment of chl using BV in first line Massimo Federico University of Modena and Reggio Emilia Italy From the book of 18FDG-PET in BV treatment patients 1 In the beginning Seattle Genetics
More informationNovel therapy for Hodgkin lymphoma
HODGKIN LYMPHOMA:NEW AND OLD Novel therapy for Hodgkin lymphoma Connie Lee Batlevi 1 and Anas Younes 1 1 Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY The treatment of Hodgkin
More informationPOST ICML Indolent lymphomas relapse treatment
POST ICML Indolent lymphomas relapse treatment Georg Hess University Medical School Johannes Gutenberg-University Mainz, Germany Treatment of relapsed indolent lymphoma 2 General categories of second line
More informationLymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège. 14 th post-ash meeting, January 6 th 2011, Brussels
Lymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège 14 th post-ash meeting, January 6 th 2011, Brussels Hodgkin s lymphoma Follicular lymphoma Diffuse large B-cell lymphoma Mantle cell
More informationOverview of Lymphoma Clinical Trials
Overview of Lymphoma Clinical Trials Dr Pam McKay Beatson West of Scotland Cancer Centre Lymphoma Action Patient Conference September 2018 Clinical trials medical research involving human participants
More informationForward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, including statements related to Seattle Genetics corporate priorities, financial guidance and anticipated upcoming activities,
More informationABVD versus BEACOPP arguments for ABVD. Dr Pauline BRICE Hôpital saint louis Université Paris VII PARIS
ABVD versus BEACOPP arguments for ABVD Dr Pauline BRICE Hôpital saint louis Université Paris VII PARIS DISCLOSURES HONORARIAS: Takeda, roche GRANT RESEARCH : Millenium Takeda, AMGEN ABVD the standard chemotherapy
More informationHodgkin Lymphoma in Older Patients
Hodgkin Lymphoma in Older Patients Andrew M. Evens, DO, MSc March 26 th, 2015 Professor of Medicine Chief, Division of Hematology/Oncology Director, Tufts Cancer Center Tufts Medical Center Elderly Hodgkin
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More informationTreatment Nodal Marginal Zone Lymphoma
Workshop : Indolent lymphomas Treatment Nodal Marginal Zone Lymphoma Catherine Thieblemont Hôpital Saint-Louis, Paris - France Bologna 16th, 2017 Ø No standardized treatment Ø Similarly treated as FL Treatment
More informationUBS European Conference 2013
UBS European Conference 2013 Tuesday, 12 November 2013 Karl Mahler, Head of Investor Relations Stefan Frings, Oncology/Immunology Therapeutic Area Head,Roche Partnering Group: Continued strong sales growth
More information58th ASH 2016 SAN DIEGO CA
58th ASH 2016 SAN DIEGO CA The best of ASH Immunotherapy PD-1/PD-L1 inhibition CART cells CRISPR Cas technology Selected oral abstracts Presidential session Late breaking abstracts Best of session Checkpoint
More informationIs there a role of HDT ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era? Yes
Is there a role of HDT ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era? Yes Bertrand Coiffier Service d Hématologie Hospices Civils de Lyon Equipe «Pathologie
More informationOSCO/OU ASH-SABC Review. Lymphoma Update. Mohamad Cherry, MD
OSCO/OU ASH-SABC Review Lymphoma Update Mohamad Cherry, MD Outline Diffuse Large B Cell Lymphoma Double Hit Lymphoma Follicular and Indolent B Cell Lymphomas Mantle Cell Lymphoma T Cell Lymphoma Hodgkin
More informationHodgkin Lymphomas: An Update
Hodgkin Lymphomas: An Update Roberto N. Miranda, M.D. Professor UT MD Anderson Cancer Center November 10 th, 2018 Disclosures Scientific Advisory Board, Allergan Inc, 2018 Hodgkin Lymphomas Classical Hodgkin
More informationVenetoclax in MCL. Prof. Le Gouill Nantes Medical University, France
Venetoclax in MCL Prof. Le Gouill Nantes Medical University, France Evasion of Apoptosis, or Cell Death, is 1. Resisting Cell Death 2. Sustained angiogenesis for growth and survival (primarily solid tumors)
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationNew Targets and Treatments for Follicular Lymphoma
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,
More informationASCO 2014 Highlights*
ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s
More informationImmuntherapie maligner Lymphome. Mathias Witzens-Harig Medizinische Klinik V Universität Heidelberg
Immuntherapie maligner Lymphome Mathias Witzens-Harig Medizinische Klinik V Universität Heidelberg 20.02.2016 Immuntherapie maligner Lymphome Allogene Stammzelltransplantation Antikörper, z.b. Rituximab
More informationDr Claire Burney, Lymphoma Clinical Fellow, Bristol Haematology and Oncology Centre, UK
EMBT LWP 2017-R-05 Research Protocol: Outcomes of patients treated with Ibrutinib post autologous stem cell transplant for mantle cell lymphoma. A retrospective analysis of the LWP-EBMT registry. Principle
More informationGenomics in diffuse large B cell lymphoma (DLBCL) not as useful as we thought. OR IS IT?
Genomics in diffuse large B cell lymphoma (DLBCL) not as useful as we thought. OR IS IT? Matt McKinney MD Instructor in Medicine, Division of Hematologic Malignancies, Department of Medicine Duke University
More informationTargeting Bruton s Tyrosine Kinase (BTK)
Targeting Bruton s Tyrosine Kinase (BTK) Lapo Alinari, MD, PhD 4 th International Conference, Translational Research in Oncology Forli, November 9-11/2016 The Ohio State University Comprehensive Cancer
More informationLINFOMA DI HODGKIN: RUOLO DEI CHECKPOINT INHIBITORS Armando Santoro
LINFOMA DI HODGKIN: RUOLO DEI CHECKPOINT INHIBITORS Armando Santoro CANCER IMMUNOTHERAPY TODAY TUMORS RESPONSIVE TO ANTI-PD1 OR ANTI-PD-L1 THERAPY! MELANOMA! RCC! NSCLC! UROTHELIAL CANCER! HEAD AND NECK
More informationENGAGE- 501: Phase 2 study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma
Published Ahead of Print on May 5, 2016, as doi:10.3324/haematol.2016.142406. Copyright 2016 Ferrata Storti Foundation. ENGAGE- 501: Phase 2 study of entinostat (SNDX-275) in relapsed and refractory Hodgkin
More informationJanssen Hematologic Malignancy Portfolio
Janssen Hematologic Malignancy Portfolio Recorded Webcast: Update for Analysts and Investors January 216 Oncology 1 Safe Harbor Statement This webcast contains "forward-looking statements" as defined in
More information